Sarilumab

From Wikipedia, the free encyclopedia - View original article

Sarilumab ?
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL6
Clinical data
Legal status ?
Identifiers
CAS number1189541-98-7 N
ATC codeNone
KEGGD10161 N
Chemical data
FormulaC6388H9918N1718O1998S44 
Mol. mass144.13 kDa
 N (what is this?)  (verify)
 
Jump to: navigation, search
Sarilumab ?
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL6
Clinical data
Legal status ?
Identifiers
CAS number1189541-98-7 N
ATC codeNone
KEGGD10161 N
Chemical data
FormulaC6388H9918N1718O1998S44 
Mol. mass144.13 kDa
 N (what is this?)  (verify)

Sarilumab is a human monoclonal antibody against the interleukin-6 receptor.

Regeneron and Sanofi are currently co-developing the drug for the treatment of rheumatoid arthritis, for which it is in phase III trials. Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[1][2]

On May 15th, 2013, both companies announced that 2 new trials were starting (COMPARE and ASCERTAIN) and the first patients had already been enrolled.[3]

On November 22nd, 2013, both companies On May 15th, 2013, both companies announced positive phase 3 results for the RA-MOBILITY trial

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab". American Medical Association. 
  2. ^ http://investor.regeneron.com/releasedetail.cfm?releaseid=590869
  3. ^ http://en.sanofi.com/Images/33027_20130515_sari_en.pdf